Vamsi Kota, MD
Hematology & Oncology · Augusta, GANPI 1790902393
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,077 of the $91,300 with a category attached, or 74.6%. 14 manufacturers reported payments, led by Novartis at 46.0% of the total. Among hematology & oncology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 93 payments — averaging $981.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$42K
- Pfizer$19K
- Servier Pharmaceuticals LLC$10K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Gilead$9K
- Apellis Pharmaceuticals, Inc.$275
- plus $756 from 8 others
Across 194 payments — averaging $7709.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$544K
- Takeda Pharmaceuticals U.S.A., Inc.$515K
- Incyte Corporation$226K
- Amgen$67K
- Astellas Pharma Global Development$48K
- E.r. Squibb & Sons, L.L.C.$27K
- plus $70K from 7 others
What the payments were for
- Consulting fees$68,07775%
- Speaking & faculty fees$17,47519%
- Travel & lodging$3,0293%
- Food & beverage$2,7023%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 46 | $42,016 |
| Pfizer | 10 | $18,691 |
| Servier Pharmaceuticals LLC | 7 | $10,091 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $10,040 |
| Gilead | 11 | $9,431 |
| Apellis Pharmaceuticals, Inc. | 3 | $275 |
| Incyte Corporation | 5 | $235 |
| Karyopharm Therapeutics Inc. | 2 | $196 |
| Sanofi-aventis U.S. LLC | 1 | $121 |
| Janssen Scientific Affairs, LLC | 2 | $88 |
| E.r. Squibb & Sons, L.L.C. | 1 | $61 |
| Bristol Myers Squibb | 1 | $24 |
| Epizyme, Inc. | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$91,300 in reported general payments places this provider in the 95th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 21 | $48,375 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 17 | $424 |
| Oxycodone Hcl | 29 | $334 |
| Acyclovir | 15 | $197 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $20 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Augusta
- Jigarkumar ParikhAugusta$267K
- Abdullah KutlarAugusta$196K
- Girindra RavalAugusta$88K
- Brent LimbaughAugusta$72K
- Amany KeruakousAugusta$36K
- Eugene LongAugusta$34K
- David SquiresAugusta$33K
- Miriam AtkinsAugusta$28K
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.